Brief: Compass Therapeutics Provides Corporate Update And Announces Advancement Of A New Drug Candidate

Compass Therapeutics

08/01/2025 13:06

Jan 8 (Reuters) - Compass Therapeutics Inc.  CMPX.O :
    * COMPASS THERAPEUTICS PROVIDES CORPORATE UPDATE AND
ANNOUNCES
ADVANCEMENT OF A NEW DRUG CANDIDATE
    * COMPASS THERAPEUTICS INC. - TOP-LINE PHASE 2/3 DATA FOR
TOVECIMIG EXPECTED END OF Q1 2025
    * COMPASS THERAPEUTICS: ESTIMATES $127 MILLION IN CASH &
MARKETABLE SECURITIES AT YE 2024, WHICH IS EXPECTED TO PROVIDE
CASH RUNWAY INTO Q1 2027
    * COMPASS THERAPEUTICS INC. - TWO PHASE 2 BIOMARKER TRIALS
EXPECTED TO INITIATE MID-2025
    * COMPASS THERAPEUTICS INC.: EXPECT TO SUBMIT AN IND BY END
OF
2025 FOR CTX-10726

Source text:  urn:newsml:reuters.com:*:nGNX6z5Lq4
Further company coverage:  CMPX.O 

 ((Reuters.Briefs@thomsonreuters.com;))